The American Cancer Society’s latest report shows a clear shift: people diagnosed with cancer are living significantly longer, thanks to better treatments, earlier detection, and smarter care. This piece walks through the big survival gains, the therapies and screening that helped drive them, and the stubborn challenges that remain as incidence and mortality trends shift.
Cancer survival has climbed sharply over the decades, and the five-year survival rate in the U.S. now sits around 70%, up from roughly 50% in the mid-1970s. That improvement reflects steady advances in therapies and diagnostic tools that find disease earlier and treat it more precisely. Researchers describe the trend as cancer “becoming less of a death sentence and more of a treatable chronic disease,” highlighting a real change in outlook for many patients.
Targeted drugs and precision approaches are changing outcomes for specific cancers. “For example, survival has improved for some types of leukemia because of the development of tyrosine kinase inhibitors, which allow most patients to have a near-normal life expectancy,” researchers noted, pointing to clear therapeutic wins. Those molecular therapies turned an often-fatal illness into a manageable condition for many people.
Survival gains are not uniform but some jumps are dramatic. Liver cancer survival rose from about 7% in the 1990s to 22% by 2023, lung cancer improved from 15% to 28%, and myeloma survival climbed from 32% to 62%. These shifts show that improvements in detection, systemic therapy, and surgical care are moving the needle across several tumor types.
The report also highlighted better outcomes for more advanced disease. “Survival has improved for people with regional-stage disease (when tumors have spread from where they started to nearby organs) and distant-stage disease (where tumors have spread to organs further away from the starting point),” the organization added. “In fact, for all distant-stage cancers combined, the relative survival rate doubled from 17% in the mid-1990s to 35% for those diagnosed from 2015 to 2021.”
Experts emphasize that statistical gains reflect smarter treatment choices driven by data and testing. The 70% five-year survival rate is a “clear signal of progress in cancer care, but statistics alone tell only part of the story.” “These previously inaccessible insights now help clinicians identify which specific treatments are most likely to benefit each patient, and which may offer little advantage.” That lets teams avoid therapies with “no added benefit” and focus novel therapies on patients who “clearly do benefit.”
Early detection and screening remain crucial ingredients in improving outcomes. Treatment advances “play a major role in this progress,” said one clinician, adding that wider use of screening mammography and annual mammograms now beginning at age 40 helps catch breast cancer at very treatable stages. Detecting disease earlier reduces both morbidity and mortality and opens the door to less invasive care.
Despite better survival, the cancer burden remains large: projections point to roughly 2.1 million new cancer cases in 2026, or about 5,800 diagnoses per day. Incidence patterns are shifting by sex and site, with breast cancer diagnosed more often than lung cancer among women, and prostate cancer remaining the leading diagnosis for men. Oral cavity, pancreatic, liver, melanoma, and uterine cancers are among those on the rise in various groups.
Experts cite multiple drivers behind the survival gains. There is “more awareness of cancer risks and symptoms, and much better screening,” and earlier diagnosis is producing earlier treatments. Advances in targeted therapy, immunotherapy, and surgical techniques, including robotics, have all contributed, and “Lifestyle changes can also help combat the effects of cancer and treatments, as well as better follow-up in terms of scans and interventions.”
Death rates are moving in the right direction overall, even as raw case counts grow. Since the peak in 1991 the cancer death rate has declined by about 34%, an improvement estimated to represent roughly 4.8 million cancer deaths prevented as of 2023. Specific declines include a 62% drop in lung cancer deaths for men since 1990 and a 38% drop for women since 2002, a 53% fall in prostate cancer deaths for men since 1993, and a 44% reduction in breast cancer mortality for women between 1989 and 2023.
